-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4

Benzinga·11/17/2025 12:29:48
Listen to the news
HC Wainwright & Co. analyst Yi Chen maintains Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and raises the price target from $3 to $4.